Global non-small cell lung cancer drugs market size is forecast to grow by USD 14.28 billion during 2019-2023 at a CAGR of 13%, with biologics segment having the largest market share. Non-small cell lung cancer drugs market analysis indicates growth will be driven by the strong drug pipeline and drug approvals. Non-small cell lung cancer drugs industry growth will also be impacted by the use of predictive biomarkers for the development of cost-effective therapies.

Competitive vendor landscape

The global non-small cell lung cancer drugs market is highly competitive with major vendors such as AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, and Merck & Co., Inc., competing based on price, quality, and product/service offerings.

Top five non-small cell lung cancer drugs market vendors

AstraZeneca

AstraZeneca operates through the biopharmaceuticals segment The company’s key offerings include: TAGRISSO, IRESSA, and IMFINZI.

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company operates in this market through its biopharmaceuticals segment. The company’s key offerings include: OPDIVO and PARAPLATIN.

Eli Lilly and Company

Eli Lilly and Company runs its operations through two segments: human pharmaceutical products and animal health products. The company’s key offerings include: ALIMTA, CYRAMZA, and PORTRAZZA.

F. Hoffmann-La Roche Ltd

F. Hoffmann-La Roche Ltd runs its operations through two segments: pharmaceuticals and diagnostics. The company’s key offerings include: TECENTRIQ, Tarceva, Avastin, and ALECENSA.

Merck & Co., Inc.

Merck & Co., Inc. runs its operations through four segments: pharmaceutical, animal health, healthcare services, and alliances. The company’s key offering is KEYTRUDA, which is used to treat advanced non-small cell lung cancer, advanced melanoma, and other types of cancer.

Looking for more information on this market? Request a free sample report